Eizen Joshua M 4
4 · AN2 Therapeutics, Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
AN2 Therapeutics (ANTX) COO/CLO Joshua M. Eizen Sells Shares
What Happened
Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics (ANTX), disposed of 5,945 shares on July 8, 2026 at $4.17 per share for a reported total of $24,803. The sale was made pursuant to the terms of a grant to satisfy tax withholding obligations arising from RSUs that vested on July 1, 2026 — a routine, tax-related sale rather than an open-market investment decision.
Key Details
- Transaction date and price: 2026-07-08, sale at $4.17 per share (total $24,803).
- Shares disposed: 5,945 (transaction code S = Sale).
- Reason for sale: Footnote F1 — sale to satisfy tax withholding on RSU vesting (code F = tax withholding).
- Shares owned after transaction: not specified in the provided excerpt; filing notes an adjusted total that includes a 5,000-share ESPP purchase on 2026-03-31 (Footnote F3).
- RSU balance/vesting (Footnote F2): includes 170,000 RSUs across four grants — 30,000 (vesting from 1/1/2024), 31,500 (from 11/4/2024), 58,500 (from 1/1/2025) and 50,000 (from 1/1/2026) — each vesting 1/4 annually over four years, subject to continued service.
- Timeliness: filing does not indicate a late report.
Context
Sales made specifically to cover tax withholding on vested RSUs are common and typically routine; they do not necessarily indicate negative views about the company. For retail investors, outright purchases or large discretionary sales are generally more informative about insider sentiment. This filing mainly documents equity compensation vesting and the routine tax-related disposition of a portion of those shares.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-07-08$4.17/sh−5,945$24,803→ 206,554 total
Footnotes (3)
- [F1]Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026.
- [F2]Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
- [F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.